Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis

Neoplasia

Volumn 12, Issue 7, 2010, Pages 516-526

  Bassi, Daniel E ^a   Zhang, Jirong ^a   Cenna, Jonathan ^a   Litwin, Samuel ^a   Cukierman, Edna ^a   Klein Szanto, Andres J P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECANOYL RVKR CHLOROMETHYLKETONE; KETONE DERIVATIVE; PROTEIN PACE4; PROTEIN TYROSINE KINASE; SERINE PROTEINASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DECANOYLRVKRCHLOROMETHYLKETONE; ENZYME INHIBITOR; PCSK6 PROTEIN, MOUSE; PEPTIDE CHLOROMETHYL KETONE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENE SEQUENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TRANSGENE; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL TRANSFORMATION; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METASTASIS; PATHOLOGY; SKIN; TRANSGENIC MOUSE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; PROPROTEIN CONVERTASES; SKIN; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954964400     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.92030     Document Type: Article

References (49)

1. Khatib AM, Siegfried G, Chretien M, Metrakos P, and Seidah NG (2002). Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am]Pathol 160, 1921-1935.
2. Steiner DF (1998). The proprotein convertases. Curr Opin Chem Bioll, 31-39.
3. Yana I and Weiss SJ (2000). Regulation of membrane type-1 matrix metallo-proteinase activation by proprotein convertases. Mol Biol Cell 11, 2387-2401.
4. Taylor NA, Van De Ven WJ, and Creemers JW (2003). Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 17, 1215-1227.
5. Thomas G (2002). Furin at the cutting edge: from protein traffic to embryo-genesis and disease. Nat Rev Mol Cell Biol 3, 753-766.
6. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, and Bassi DE (2007). Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 29, 289-299.
7. Cheng M, Watson PH, Paterson JA, Seidah N, Chretien M, and Shiu RP (1997). Pro-protein convertase gene expression in human breast cancer. Int J Cancer 71, 966-971.
8. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, Metrakos P, and Seidah NG (2001). Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. Biol Chem 276, 30686-30693.
9. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, and Klein-Szanto AJ (2002). Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 8, 1740-1746.
10. Bassi DE, Mahloogi H, Lopez De Cicco R, and Klein-Szanto A (2003). Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162, 439-47.
11. Remacle AG, Shiryaev SA, Oh ES, Cieplak P Srinivasan A, Wei G, Liddington RC, RatnikovBI, ParentA, and DesjardinsR (2008). Substrate cleavage analysis of furin and related proprotein convertases. A comparative study./Biol Chem 283, 20897-20906.
12. 1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 95, 7293-7298.
13. KomiyamaT, VanderLugt B, Fugere M, Day R Kaufman RJ, and Fuller RS (2003). Optimization of protease-inhibitor interactions by randomizing adventitious contacts. Proc Natl Acad Sci USA 100, 8205-8210.
14. Scamuffa N, Calvo F, Chretien M, Seidah NG, and Khatib AM (2006). Proprotein convertases: lessons from knockouts. FASEB J 20, 1954-1963.
15. Bassi DE, Lopez De Cicco R CennaJ, Litwin S, Cukierman E, and Klein-Szanto AJ (2005). PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. CancerRes65, 7310-7319.
16. Mains RE, Berard CA, Denault JB, Zhou A, Johnson RC, and Leduc R (1997). PACE4: a subtilisin-like endoprotease with unique properties. Biochem /321, 587-593.
17. Nagahama M, Taniguchi T Hashimoto E, Imamaki A, Mori K, Tsuji A, and Matsuda Y (1998). Biosynthetic processing and quaternary interactions of proprotein convertase SPC4 (PACE4). FEBS Lett 434, 155-159.
18. Tsuji A (2003). Extracellular processing protease PACE4: significance of diversity of SPC family proteases. Seikagaku 75, 305-310.
19. Nour N, Mayer G, Mort JS, Salvas A, Mbikay M, Morrison CJ, Overall CM, and Seidah NG (2005). The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. Mol Biol Cell 16, 5215-5226.
20. Mayer G, Hamelin J, Asselin MC, Pasquato A, Marcinkiewicz E, Tang M, Tabibzadeh S, and Seidah NG (2008). The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates./Biol Chem 283, 2373-2384.
21. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Clierel G, Calvo F, Seidah NG, and Khatib AM (2008). Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 118, 352-363.
22. Lapierre M, Siegfried G, Scamuffa N, Bontemps Y, Calvo F, Seidah NG, and Khatib AM (2007). Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1. Cancer Res 67, 9030-9034.
23. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, and Klein-Szanto AJ (2001). Furin inhibition results in absent or decreased invasiveness and tumori-genicity of human cancer cells. Proc Natl Acad Sci USA 98, 10326-10331.
24. Lopez de Cicco R, Bassi DE, Zucker S, Seidah NG, and Klein-Szanto AJ (2005). Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res 65, 4162-A171.
25. Lissitzky JC, Luis J, Munzer JS, Benjannet S, Parat F, Chretien M, Marvaldi J, and Seidah NG (2000). Endoproteolytic processing of integrin pro-a subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7. Biochem J 346, 133-138.
26. Angliker H, Wikstrom P, Shaw E, Brenner C, and Fuller RS (1993). The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 293, 75-81.
27. Akamatsu T, Azlina A, Purwanti N, Karabasil MR, Hasegawa T, Yao C, and Hosoi K (2008). Inhibition and transcriptional silencing of a subtilisin-like proprotein convertase, PACE4/SPC4, reduces the branching morphogenesis of and AQP5 expression in rat embryonic submandibular gland. Dev Biol 325, 434-443.
28. Kacprzak MM, Peinado JR, Than ME, Appel J, Henrich S, Lipkind G, Houghten RA, Bode W and Lindberg I (2004). Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nonsL-D-arginme. J Biol Chem 279, 36788-36794.
29. Basak A and Lazure C (2003). Synthetic peptides derived from the prosegments of proprotein convertase 1/3 and furin are potent inhibitors of both enzymes. Biochem J 373, 231-239.
30. Hennings H, Robinson VA, Michael DM, Pettit GR, Jung R, and Yuspa SH (1990). Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters. Cancer Res 50, 4794-4800.
31. Hubbard FC, Goodrow TL, Liu SC, Brilliant MH, Basset P, Mains RE, and Klein-Szanto AJ (1997). Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability. Cancer Res 57, 5226-5231.
32. Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, and Thomas G (1992). Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. Biol Chem 267, 16396-16402.
33. Lopez de Cicco R, Watson JC, Bassi DE, Litwin S, and Klein-Szanto AJ (2004). Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res 10, 4480-4488.
34. Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, and Bova S (1998). Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4, 1887-1898.
35. Mahloogi H, Bassi DE, and Klein-Szanto AJ (2002). Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 23, 565-572.
36. Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, and Slaga TJ (1988). In vivo behavior of murine epidermal cell lines derived from initiated and noninitiated skin. Cancer Res 48, 435-439.
37. White PJ, Gray AC, Fogarty RD, Sinclair RD, Thumiger SP, Werther GA, and Wraight CJ (2002). C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application./Invest Dermatol 118, 1003-1007.
38. Spiegelman VS, BudunovalV, CarbajalS, and Slaga TJ (1997). Resistance of transformed mouse keratinocytes to growth inhibition by glucocorticoids. Mol Carcinog 20, 99-107.
39. Baserga R, Peruzzi F, and Reiss K (2003). The IGF-1 receptor in cancer biology. Int J Cancer 107, 873-877.
40. Larsson O, Girnita A, and Girnita L (2005). Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92, 2097-2101.
41. BurgaudJL, Resnicoff M, and Baserga R (1995). Mutant IGF-I receptors as dominant negatives for growth and transformation. Commun 214, 475-481.
42. Prager D, Li HL, Asa S, and Melmed S (1994). Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 91, 2181-2185.
43. WilkerE, Bol D, Kiguchi K, Rupp T, Beltran L, and DiGiovanni J (1999). Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulinlike growth factor-1 receptor in the epidermis of transgenic mice. Mol Carcinog 25, 122-131.
44. DiGiovanni J, Bol DK, Wilker E, Beltran L, Carbajal S, Moats S, Ramirez A, Jorcano J, and Kiguchi K (2000). Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res 60, 1561-1570.
45. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, and Baserga R (1993). Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90, 11217-11221.
46. Sadagurski M, Yakar S, Weingarten G, Holzenberger M, Rhodes CJ, Breitkreutz D, Leroith D, and Wertheimer E (2006). Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol 26, 2675-2687.
47. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, Seidah NG, and Khatib AM (2003). The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111, 1723-1732.
48. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, Rothacker J, Nice EC, Harder KW, Roufail S, Hibbs ML, et al. (2007). Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. FASEB J 21, 1088-1098.
49. Fu Y, Campbell EJ, Shepherd TG, and Nachtigal MW (2003). Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 1, 569-576.